Arbutus Biopharma Corp Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Arbutus Biopharma Corp (ABUS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $304.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-23
- Arbutus Biopharma Corp effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $304.00K, a 77.09% decline from fiscal 2024.
- Arbutus Biopharma Corp effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.33M.
- Arbutus Biopharma Corp effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$187.00K, a 137.10% decline from fiscal 2022.
- Arbutus Biopharma Corp effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $504.00K, a 10.53% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $304.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $1.33M 10-K · filed 2026-03-23 |
| 2023-12-31 | -$187.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | $504.00K 10-K · filed 2024-03-05 |
| 2021-12-31 | $456.00K 10-K · filed 2023-03-02 |
| 2020-12-31 | $450.00K 10-K · filed 2022-03-03 |
| 2019-12-31 | $523.00K 10-K · filed 2021-03-04 |
| 2018-12-31 | $1.69M 10-K · filed 2020-03-05 |
| 2017-12-31 | $3.13M 10-K · filed 2019-03-07 |
| 2016-12-31 | $9.73M 10-K · filed 2018-03-16 |
| 2015-12-31 | $7.34M 10-K · filed 2018-03-16 |
| 2014-12-31 | $904.00K 10-K · filed 2017-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |